DEA policy has not stopped marijuana use. It has blocked honest research and left Americans with less reliable facts.
Quick Take
- Federal health officials recommended moving marijuana to Schedule III in 2023.[2]
- Schedule III rules are lighter than Schedule I rules, which makes research easier.[1][12]
- DEA will hold a new hearing on broader rescheduling, but the agency has drawn fire for limiting who can testify.[1][21]
- Rescheduling would not legalize recreational marijuana, but it could ease research and tax burdens.[12][16]
Federal Review Finally Acknowledges Medical Use
In August 2023, the United States Department of Health and Human Services recommended that marijuana move to Schedule III under the Controlled Substances Act.[2] That recommendation said marijuana meets Schedule III standards because it has a lower abuse risk than Schedule I drugs and has a currently accepted medical use in treatment.[2] For years, federal policy treated cannabis as if the evidence did not matter. The new review shows that claim is no longer easy to defend.
The core issue is not whether marijuana exists in American life. It clearly does. The real issue is whether Washington will let scientists study it without needless roadblocks. Sources in the record say Schedule I status creates strict registration rules, limits sourcing, and slows research.[1][3] A Brookings transcript from 2016 made the same basic point: rescheduling would not legalize marijuana, but it would lower the barriers to empirical, double-blind, and placebo studies.[12]
Research Barriers Still Matter
That point should matter to any serious policy debate. If federal law makes research harder, then lawmakers, doctors, and parents get weaker information. The National Center for Biotechnology Information says federal cannabis restrictions have limited research in the United States and left patients, health care workers, and policymakers without the evidence they need.[3] That is the ugly truth behind decades of drug war policy. It did not end use. It starved the public of better data.
The proposed move to Schedule III would not solve every problem overnight. The Yale Law Journal notes that rescheduling does not legalize marijuana and does not erase the larger federal-state conflict.[4] Brookings said the same years ago, when it explained that Schedule II or Schedule III status would only make modest changes for researchers.[12] Still, modest is not nothing. In a system this broken, even smaller reforms can help restore some common sense.
DEA Hearing Raises Questions About Fairness
DEA’s new hearing has also drawn sharp criticism because the agency reportedly denied participation to major reform groups and selected only opponents of rescheduling.[1] That includes the National Organization for the Reform of Marijuana Laws, the Marijuana Policy Project, the National Cannabis Industry Association, and the United States Cannabis Roundtable.[1] A hearing that excludes one side of a major dispute does not inspire confidence. Americans know a rigged process when they see one.
"A Drug Enforcement Administration (DEA) judge has issued an order laying out the schedule for a hearing on the Trump administration’s move to reschedule cannabis that is set to start next week."#Marijuana #Cannabis #DEA #Rescheduling #Hearing #Schedule https://t.co/Tvt8kd54qd
— Omni Medical Services (@omnimedicalmmj) June 25, 2026
The legal stakes are also narrower than some headlines suggest. The Justice Department said in 2024 that placing state medical marijuana products in Schedule III would ease medical research.[21] But it would not make adult-use marijuana legal, and it would not put cannabis on pharmacy shelves without more federal action.[12][16] That distinction matters. Conservatives should favor rule of law, but they should also reject a system that hides behind outdated red tape when the facts have already changed.
What the Change Would and Would Not Do
Rescheduling could also affect taxes. Harvard Law School discussion materials cited in the research package say Section 280E does not apply to Schedule III drugs.[5] That could ease the burden on state-licensed providers that now face heavy federal tax pressure. Supporters also argue that moving marijuana out of Schedule I would improve the quality of research and help doctors learn more about dosage, safety, and medical use.[2][12][20] Those are practical gains, not slogans.
At the same time, the record does not support pretending this is full legalization. The Yale Law Journal and other legal analyses note that rescheduling would not remove all federal controls, and it would not end the federal-state split.[4][16][17] That is why the strongest case here is simple: if the federal government is going to regulate marijuana, it should at least stop making scientists jump through hoops to study it. The country has waited long enough for honest answers.
Sources:
[1] Web – Prohibition Didn’t Stop Marijuana Use. It Stopped Marijuana Research.
[2] Web – DEA Selects Only Those Opposed to Rescheduling for Hearing
[3] Web – Federal Marijuana Rescheduling: Process and Impact
[4] Web – Prohibition Didn’t Stop Marijuana Use. It Stopped Marijuana Research.
[5] Web – Decriminalizing Cannabis | Yale Law Journal
[12] Web – Evidence Suggests the DEA Still Resists Rescheduling Marijuana
[16] Web – Here’s Why the DEA Will Never Reschedule Cannabis
[17] Web – Oops, We Did It Again? Executive Action Revives Federal Marijuana …
[20] YouTube – The Law, Policy, and Politics of Rescheduling Cannabis
[21] Web – Effects of the Federal Government’s Move to Reschedule Cannabis
